More than a third of high-risk leukemia patients respond to an experimental new drug

A new drug for patients with acute myeloid leukemia marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

http://medicalxpress.com/news/2012-12-high-risk-leukemia-patients-experimental-drug.html